Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus SODIUM CHLORIDE 23 4 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus SODIUM CHLORIDE 23 4 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN PLASTIC CONTAINER vs SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Sodium chloride 23.4% is a hypertonic saline solution that increases serum osmolality, drawing water from intracellular space into extracellular space, thereby expanding intravascular volume and reducing cerebral edema. It also acts as an electrolyte replenisher.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
IV: 50-100 mL of 23.4% sodium chloride (11.7-23.4 g NaCl) infused over 1-2 hours for hyponatremia; rate not to exceed 0.5 mEq/L/h correction.
None Documented
None Documented
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Not applicable as a terminal elimination half-life; sodium and chloride are electrolytes regulated by homeostatic mechanisms; plasma concentrations normalize within minutes to hours depending on volume status and renal function.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Renal; >95% of administered sodium and chloride ions excreted unchanged in urine via glomerular filtration and tubular reabsorption/regulation; negligible biliary/fecal elimination.
Category C
Category A/B
Electrolyte
Electrolyte